Prof Jens Bedke speaks to ecancer about the results of the SUNNIFORECAST trial.

This study investigates the effectiveness of ipilimumab and nivolumab as a first-line treatment for metastatic non-clear cell renal cell carcinoma, comparing it to standard TKI monotherapy.

The trial achieved an impressive overall survival rate of over 86% after 12 months despite challenges in progression-free survival.

Specific patient subgroups, especially PD-1-positive individuals, showed notable benefits, highlighting the need for tailored treatment approaches.